These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 27296648)

  • 1. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
    Arcangeli S; Greco C
    Nat Rev Urol; 2016 Jul; 13(7):400-8. PubMed ID: 27296648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
    Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K
    Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated Radiotherapy for Localized Prostate Cancer: When and for Whom?
    Roy S; Morgan SC
    Curr Urol Rep; 2019 Jul; 20(9):53. PubMed ID: 31359187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hypofractionated irradiation of prostate cancer: What is the radiobiological understanding in 2017?].
    Cosset JM
    Cancer Radiother; 2017 Oct; 21(6-7):447-453. PubMed ID: 28847464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of hypofractionation for primary management of prostate cancer.
    Koontz BF; Bossi A; Cozzarini C; Wiegel T; D'Amico A
    Eur Urol; 2015 Oct; 68(4):683-91. PubMed ID: 25171903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
    Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated radiation therapy for prostate cancer: The McGill University Health Center experience.
    Barbosa Neto O; Souhami L; Faria S
    Cancer Radiother; 2015 Oct; 19(6-7):431-6. PubMed ID: 26278988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the best way to radiate the prostate in 2016?
    Moon DH; Efstathiou JA; Chen RC
    Urol Oncol; 2017 Feb; 35(2):59-68. PubMed ID: 27395453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
    Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
    JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer: Hypofractionated radiotherapy confirmed effective and safe.
    Thoma C
    Nat Rev Urol; 2016 Aug; 13(8):435. PubMed ID: 27377157
    [No Abstract]   [Full Text] [Related]  

  • 13. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
    Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
    Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Which rules apply to hypofractionated radiotherapy?].
    Supiot S; Clément-Colmou K; Paris F; Corre I; Chiavassa S; Delpon G
    Cancer Radiother; 2015 Oct; 19(6-7):421-5. PubMed ID: 26321647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiotherapy for Primary Prostate Cancer.
    Kothari G; Loblaw A; Tree AC; van As NJ; Moghanaki D; Lo SS; Ost P; Siva S
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818789633. PubMed ID: 30064301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations.
    Langrand-Escure J; de Crevoisier R; Llagostera C; Créhange G; Delaroche G; Lafond C; Bonin C; Bideault F; Sargos P; Belhomme S; Pasquier D; Latorzeff I; Supiot S; Hennequin C
    Cancer Radiother; 2018 Apr; 22(2):193-198. PubMed ID: 29628205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal scheduling of hypofractionated radiotherapy for localized prostate cancer: A systematic review and metanalysis of randomized clinical trials.
    Arcangeli G; Arcangeli S; Pinzi V; Benassi M; Benassi M; Strigari L
    Cancer Treat Rev; 2018 Nov; 70():22-29. PubMed ID: 30053726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypofractionated radiotherapy of prostate adenocarcinoma: Towards a new standard?].
    Mazeron JJ; Magne N; Thariat J
    Bull Cancer; 2016 Nov; 103(11):903-904. PubMed ID: 27842862
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypofractionated radiotherapy for localized prostate cancer.
    Höcht S; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Hölscher T; Martin T; Sedlmayer F; Wenz F; Zips D; Wiegel T
    Strahlenther Onkol; 2017 Jan; 193(1):1-12. PubMed ID: 27628966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.